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General Remarks 
Unless otherwise noted, all reagents were obtained from commercial suppliers and 
used without further purification. CHCl3 was distilled over P2O5. Reactions were 
monitored by thin-layer chromatography (TLC) using commercial silica gel 
HSGF254 plates. Column chromatography was performed on Silica Gel 60 (E. Merck, 
230-400 mesh). The 1H (400 MHz) and 13C NMR (100.6 MHz) spectra were recorded 
with Bruker AM-400 spectrometer in CDCl3 solution. Chemical shifts were 
referenced with tetramethylsilane (0 ppm for 1H and 77.0 ppm for 13C). The 
HR-ESI-MS data were measured on a Bruker Apex IV FTMS. Enantiomeric ratio (er) 
was determined with Daicel Chiralcel AS-H column (25 cm - 0.46 cm ID, 
n-hexane/i-PrOH = 30:70, 1 mL/min, 220 nm). 
 
General procedure for the preparation of 4 
An oven-dried 10 mL vial was charged with O-pivaloylated β-D-galactosylimine 
(0.15 mmol) and Sc(OTf)3 (0.075 mmol). After the vessel was treated with alternating 
vacuum and nitrogen purge, 1 mL of dry CHCl3 was added via a syringe, and the 
mixture was stirred under N2 at -40 for 15 min before 3, 4-2H-pyran or 2, 
3-2H-furan (0.15 mmol) and MeOH or i-PrOH (0.225 mmol, 1.5 equiv) were added. 
The resulting solution was stirred for the indicated time until the reaction was 
complete as shown by TLC (usually 24h). Then three drops of triethylamine were 
added and the mixture was gradually warmed to room temperature. After extracted 
with CH2Cl2, the organic layer was washed with saturated aqueous NaHCO3, dried 
over MgSO4, filtered, and the volatiles were removed under vacuum. The residue was 
purified by column chromatography on silica gel (petroleum ether/ethyl acetate = 
15/1), yielding the corresponding compounds 4aa-gb as a mixture of 4~8 
diastereomers. 
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(2S,3R)-2-methoxy-3-[(S)-4-nitrophenyl(2,3,4,6-tetra-O-pivaloyl-β-D-galactosyla
mino)methyl]tetrahydro-2H-pyran (4aa) 
 
1H NMR (400 MHz, CDCl3) δ 8.18 (d, J = 8.7 Hz, 2H), 7.43 (d, J = 8.7 Hz, 2H), 5.33 (d, J = 2.5 Hz, 
1H), 5.07 (dd, J = 10.2, 8.8 Hz, 1H), 4.98 (dd, J = 10.3, 3.3 Hz, 1H), 4.34 (d, J = 7.6 Hz, 1H), 4.15 (dd, 
J = 11.1, 6.9 Hz, 1H), 4.03 – 3.84 (m, 3H), 3.66 (dd, J = 12.9, 8.5 Hz, 2H), 3.53 (s, 3H), 3.23 (d, J = 
12.9 Hz, 1H), 1.86 – 1.62 (m, J = 11.6, 7.5, 3.8 Hz, 1H), 1.55 – 1.31 (m, 3H), 1.27 (s, 9H), 1.21 (s, 9H), 
1.19 (s, 9H), 1.09 (s, 9H), 1.01 – 0.74 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 177.85, 177.28, 177.10, 
176.77, 148.51, 147.45, 129.49, 123.34, 105.59, 86.22, 71.57, 71.37, 68.88, 67.32, 65.22, 61.66, 57.97, 
55.71, 45.32, 39.03, 38.78, 38.70, 38.68, 27.27, 27.17, 27.11, 27.06, 24.83, 24.43. HR-ESI-MS: Calcd 
for C39H60N2O13 [M+H]+: 765.4168, found: 765.4156. 
 
(2S,3R)-2-methoxy-3-[(S)-4-chlorophenyl(2,3,4,6-tetra-O-pivaloyl-β-D-galactosyl
amino)methyl]tetrahydro-2H-pyran (4ba) 
 
 
1H NMR (400 MHz, CDCl3) δ 7.28 (d, J = 8.4 Hz, 2H), 7.17 (d, J = 8.4 Hz, 2H), 5.32 (d, J = 2.5 Hz, 
1H), 5.06 (dd, J = 10.3, 7.6 Hz, 1H), 4.98 (dd, J = 10.3, 3.3 Hz, 1H), 4.22 (d, J = 7.5 Hz, 1H), 4.13 (dd, 
J = 11.1, 6.9 Hz, 1H), 3.99 – 3.88 (m, 3H), 3.74 – 3.61 (m, 2H), 3.51 (s, 3H), 3.04 (d, J = 12.8 Hz, 1H), 
1.70 – 1.60 (m, J = 15.5, 7.6, 3.9 Hz, 1H), 1.50 – 1.37 (m, 3H), 1.26 (s, 9H), 1.20 (s, 9H), 1.18 (s, 9H), 
1.09 (s, 9H), 0.82 – 0.74 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 177.89, 177.32, 177.12, 176.83, 
138.84, 133.07, 130.10, 128.26, 105.75, 86.13, 71.48, 71.45, 68.92, 67.47, 65.23, 61.78, 57.61, 55.69, 
45.40, 39.04, 38.76, 38.71, 38.69, 27.27, 27.19, 27.13, 27.08, 24.92, 24.23. HR-ESI-MS: Calcd for 
C39H60ClNO11 [M+H]+: 754.3927, found: 754.3913. 
 
(2S,3R)-2-methoxy-3-[(S)-4-fluorophenyl(2,3,4,6-tetra-O-pivaloyl-β-D-galactosyla
mino)methyl]tetrahydro-2H-pyran (4ca) 
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1H NMR (400 MHz, CDCl3) δ 7.20 (dd, J = 8.6, 5.6 Hz, 2H), 6.99 (t, J = 8.6 Hz, 2H), 5.32 (d, J = 2.5 
Hz, 1H), 5.06 (dd, J = 11.7, 7.3 Hz, 1H), 4.98 (dd, J = 10.3, 3.3 Hz, 1H), 4.21 (d, J = 7.5 Hz, 1H), 4.13 
(dd, J = 11.1, 6.9 Hz, 1H), 4.01 – 3.89 (m, 3H), 3.75 – 3.61 (m, 2H), 3.51 (s, 3H), 3.06 (d, J = 12.8 Hz, 
1H), 1.69 – 1.61 (m, 1H), 1.49 – 1.36 (m, 3H), 1.27 (s, 9H), 1.21 (s, 9H), 1.18 (s, 9H), 1.09 (s, 9H), 
0.95 – 0.85 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 177.90, 177.31, 177.15, 176.84, 135.93, 135.90, 
130.19, 130.12, 115.01, 114.80, 105.83, 86.13, 71.50, 71.41, 68.90, 67.47, 65.19, 61.78, 57.57, 55.68, 
45.45, 39.03, 38.75, 38.70, 27.25, 27.18, 27.12, 27.07, 24.90, 24.26. HR-ESI-MS: Calcd for 
C39H60FNO11 [M+H]+: 738.4223, found: 738.4213. 
 
(2R,3R)-2-isopropoxy-3-[(S)-4-nitrophenyl(2,3,4,6-tetra-O-pivaloyl-β-D-galactosy
lamino)methyl]tetrahydro-2H-pyran (4da) 
 
1H NMR (400 MHz, CDCl3) δ 8.18 (d, J = 8.7 Hz, 2H), 7.42 (d, J = 8.7 Hz, 2H), 5.35 (d, J = 2.7 Hz, 
1H), 5.10 (dd, 1H), 4.95 (dd, J = 10.3, 3.4 Hz, 1H), 4.34 (d, J = 7.9 Hz, 1H), 4.23 – 4.02 (m, 4H), 3.92 
(dd, J = 11.1, 7.2 Hz, 2H), 3.63 (t, J = 7.0 Hz, 1H), 3.58 – 3.49 (m, 1H), 3.35 (td, J = 11.5, 3.1 Hz, 1H), 
1.76 – 1.59 (m, 1H), 1.47 – 1.39 (m, 1H), 1.37 (d, J = 1.4 Hz, 3H), 1.36 (d, J = 1.5 Hz, 3H), 1.25 (s, 
9H), 1.20 (s, 9H), 1.20 (s, 9H), 1.08 (s, 9H), 1.01 – 0.72 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 
177.90, 177.08, 177.03, 176.77, 149.06, 147.50, 129.53, 123.48, 103.98, 86.29, 71.53, 71.33, 70.62, 
68.52, 67.37, 65.54, 61.55, 59.38, 45.11, 38.99, 38.76, 38.73, 38.68, 27.29, 27.15, 27.08, 26.63, 25.00, 
23.78, 21.73. HR-ESI-MS: Calcd for C41H64N2O13 [M+H]+: 793.4481, found: 793.4460. 
 
(2R,3R)-2-isopropoxy-3-[(S)-4-chlorophenyl(2,3,4,6-tetra-O-pivaloyl-β-D-galactos
ylamino)methyl]tetrahydro-2H-pyran (4ea) 
 
1H NMR (400 MHz, CDCl3) δ 7.27 (d, J = 8.4 Hz, 2H), 7.16 (d, J = 8.4 Hz, 2H), 5.34 (d, J = 2.7 Hz, 
1H), 5.09 (dd, J = 10.1, 9.2 Hz, 1H), 4.96 (dd, J = 10.3, 3.4 Hz, 1H), 4.31 (d, J = 7.9 Hz, 1H), 4.16 – 
3.94 (m, 4H), 3.94 – 3.88 (m, 2H), 3.73 – 3.52 (m, 2H), 3.33 (td, J = 11.4, 2.9 Hz, 1H), 1.69 – 1.60 (m, 
1H), 1.36 (d, J = 1.6 Hz, 3H), 1.35 (d, J = 1.6 Hz, 3H), 1.25 (s, 9H), 1.20 (s, 9H), 1.19 (s, 9H), 1.08 (s, 
9H), 0.99 – 0.86 (m, 2H), 0.86 – 0.76 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 177.91, 177.09, 177.06, 
176.80, 139.49, 133.04, 130.08, 128.33, 104.29, 86.20, 71.43, 71.34, 70.58, 68.55, 67.50, 65.59, 61.65, 
59.13, 45.17, 39.02, 38.98, 38.71, 38.66, 27.27, 27.14, 27.13, 27.07, 26.60, 25.12, 23.78, 21.73. 
HR-ESI-MS: Calcd for C41H64ClNO11 [M+H]+: 782.4240, found: 782.4225. 
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(2R,3R)-2-isopropoxy-3-[(S)-4-fluorophenyl(2,3,4,6-tetra-O-pivaloyl-β-D-galactos
ylamino)methyl]tetrahydro-2H-pyran (4fa) 
 
1H NMR (400 MHz, CDCl3) δ 7.18 (dd, J = 8.5, 5.6 Hz, 2H), 6.98 (t, J = 8.6 Hz, 2H), 5.34 (d, J = 2.9 
Hz, 2H), 5.09 (dd, J = 11.6, 7.7 Hz, 2H), 4.96 (dd, J = 10.3, 3.4 Hz, 1H), 4.32 (d, J = 7.8 Hz, 1H), 4.18 
– 3.98 (m, 3H), 3.97 – 3.86 (m, 3H), 3.73 – 3.52 (m, 2H), 3.33 (td, J = 11.4, 2.9 Hz, 1H), 1.74 – 1.51 
(m, 2H), 1.36 (d, J = 2.0 Hz, 3H), 1.35 (d, J = 2.1 Hz, 3H), 1.25 (s, 9H), 1.20 (s, 9H), 1.18 (s, 9H), 1.08 
(s, 9H), 1.00 – 0.72 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 177.94, 177.14, 177.07, 176.82, 136.56, 
130.18, 130.10, 115.09, 114.88, 104.35, 86.21, 71.49, 71.33, 70.58, 68.56, 67.53, 65.58, 61.68, 59.04, 
45.27, 38.99, 38.71, 38.67, 27.26, 27.15, 27.13, 27.08, 26.61, 25.15, 23.79, 21.73. HR-ESI-MS: Calcd 
for C41H64FNO11 [M+H]+: 766.4536, found: 766.4517. 
 
(2R,3R)-2-isopropoxy-3-[(S)-4-bromophenyl(2,3,4,6-tetra-O-pivaloyl-β-D-galacto
sylamino)methyl]tetrahydro-2H-pyran (4ga) 
 
1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 8.3 Hz, 2H), 7.11 (d, J = 8.3 Hz, 2H), 5.34 (d, J = 2.7 Hz, 
1H), 5.09 (dd, J = 11.3, 8.0 Hz, 1H), 4.96 (dd, J = 10.3, 3.4 Hz, 1H), 4.31 (d, J = 7.9 Hz, 1H), 4.19 – 
4.05 (m, 2H), 4.04 – 3.96 (m, 1H), 3.95 – 3.84 (m, 3H), 3.73 – 3.51 (m, 2H), 3.33 (td, J = 11.4, 3.0 Hz, 
1H), 1.66 – 1.55 (m, 1H), 1.47 – 1.37 (m, 2H), 1.36 (d, J = 1.1 Hz, 3H), 1.34 (d, J = 1.3 Hz, 3H), 1.25 
(s, 9H), 1.20 (s, 9H), 1.19 (s, 9H), 1.08 (s, 9H), 0.94 – 0.75 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 
177.90, 177.07, 177.05, 176.79, 140.03, 131.28, 130.47, 121.14, 104.27, 86.19, 71.42, 71.34, 70.57, 
68.54, 67.50, 65.58, 61.65, 59.18, 45.12, 38.97, 38.70, 38.65, 27.26, 27.13, 27.12, 27.07, 26.58, 25.11, 
23.77, 21.72. HR-ESI-MS: Calcd for C41H64BrNO11 [M+H]+: 826.3735, found: 826.3721. 
 
(2R,3R)-2-isopropoxy-3-[(S)-4-cyanophenyl(2,3,4,6-tetra-O-pivaloyl-β-D-galactos
ylamino)methyl]tetrahydro-2H-pyran (4ha) 
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1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 8.2 Hz, 2H), 7.36 (d, J = 8.2 Hz, 2H), 5.35 (d, J = 2.6 Hz, 
1H), 5.09 (dd, J = 10.2, 9.0 Hz, 1H), 4.96 (dd, J = 10.3, 3.4 Hz, 1H), 4.33 (d, J = 7.9 Hz, 1H), 4.18 – 
4.05 (m, 3H), 4.02 (d, J = 9.0 Hz, 1H), 3.97 – 3.86 (m, 2H), 3.78 – 3.67 (m, 2H), 3.63 (t, J = 7.2 Hz, 
1H), 3.53 (dd, J = 13.1, 8.9 Hz, 1H), 3.35 (td, J = 11.4, 3.1 Hz, 1H), 1.37 (d, 3H), 1.35 (d, J = 0.9 Hz, 
3H), 1.25 (s, 9H), 1.20 (s, 9H), 1.19 (s, 9H), 1.08 (s, 9H), 1.05 – 0.97 (m, 1H), 0.93 – 0.77 (m, 1H). 13C 
NMR (101 MHz, CDCl3) δ 177.91, 177.10, 177.01, 176.77, 146.96, 132.04, 129.50, 118.70, 111.46, 
104.03, 86.27, 71.45, 71.33, 70.61, 68.50, 67.35, 65.55, 61.53, 59.65, 58.45, 45.03, 38.98, 38.73, 38.72, 
38.67, 27.27, 27.13, 27.13, 27.07, 26.63, 25.01, 23.77, 21.72, 18.42. HR-ESI-MS: Calcd for 
C42H64N2O11 [M+H]+: 773.4582, found: 773.4574. 
 
(2S,3R)-2-methoxy-3-[(S)-4-nitrophenyl(2,3,4,6-tetra-O-pivaloyl-β-D-galactosyla
mino)methyl]tetrahydro-2H-furan (4ab) 
 
1H NMR (400 MHz, CDCl3) δ 8.18 (d, J = 8.7 Hz, 2H), 7.45 (d, J = 8.7 Hz, 2H), 5.36 (d, J = 2.2 Hz, 
1H), 5.07 (dd, J = 10.3, 8.2 Hz, 1H), 5.02 (dd, J = 3.1, 10.3 Hz,, 1H), 4.94 (d, J = 3.5 Hz, 1H), 4.17 (dd, 
J = 11.1, 6.8 Hz, 1H), 4.09 (d, J = 9.7 Hz, 1H), 3.96 (dd, J = 11.1, 6.9 Hz, 1H), 3.90 – 3.67 (m, 4H), 
3.43 (s, 3H), 2.37 – 2.15 (m, J = 17.4, 9.4, 3.5 Hz, 1H), 1.63 – 1.48 (m, 1H), 1.48 – 1.33 (m, J = 9.5, 
7.1, 6.5 Hz, 1H), 1.28 (s, 9H), 1.21 (s, 9H), 1.15 (s, 9H), 1.10 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 
177.81, 177.38, 177.09, 176.73, 149.62, 147.52, 128.71, 123.64, 108.40, 86.47, 71.60, 71.30, 68.78, 
67.15, 66.69, 61.43, 59.36, 55.47, 52.08, 39.03, 38.75, 38.69, 29.44, 27.29, 27.20, 27.17, 27.09, 27.04. 
HR-ESI-MS: Calcd for C38H57N2O13 [M+H]+: 751.4011, found: 751.3995. 
 
(2R,3R)-2-isopropoxy-3-[(S)-4-nitrophenyl(2,3,4,6-tetra-O-pivaloyl-β-D-galactosy
lamino)methyl]tetrahydro-2H-furan (4db) 
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1H NMR (400 MHz, CDCl3) δ 8.17 (d, J = 8.7 Hz, 2H), 7.46 (d, J = 8.7 Hz, 2H), 5.37 (d, J = 2.2 Hz, 
1H), 5.15 (d, J = 4.4 Hz, 1H), 5.11 – 4.96 (m, 2H), 4.19 (dd, J = 11.1, 6.8 Hz, 1H), 4.11 (d, J = 10.4 Hz, 
1H), 4.04 – 3.90 (m, 2H), 3.89 – 3.67 (m, 4H), 2.38 – 2.07 (m, 1H), 1.49 – 1.35 (m, 2H), 1.33 (d, J = 
6.1 Hz, 3H), 1.28 (d, J = 6.1 Hz, 3H), 1.26 (s, 9H), 1.21 (s, 9H), 1.17 (s, 9H), 1.09 (s, 9H). 13C NMR 
(101 MHz, CDCl3) δ 177.84, 177.27, 177.08, 176.74, 149.77, 147.58, 128.73, 123.64, 105.91, 86.44, 
71.71, 71.27, 70.44, 68.54, 67.23, 66.56, 61.46, 59.68, 51.85, 39.00, 38.77, 38.74, 38.70, 30.02, 27.26, 
27.14, 27.12, 27.07, 23.58, 21.96. HR-ESI-MS: Calcd for C40H62FNO11 [M+H]+: 779.4324, found: 
779.4306. 
 
(2R,3R)-2-isopropoxy-3-[(S)-4-chlorophenyl(2,3,4,6-tetra-O-pivaloyl-β-D-galactos
ylamino)methyl]tetrahydro-2H-furan (4eb) 
 
1H NMR (400 MHz, CDCl3) δ 7.27 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 8.4 Hz, 2H), 5.36 (d, J = 2.6 Hz, 
1H), 5.11 (d, J = 4.4 Hz, 1H), 5.09 – 4.98 (m, 2H), 4.16 (dd, J = 11.1, 6.8 Hz, 1H), 4.03 – 3.89 (m, 3H), 
3.87 – 3.66 (m, 4H), 2.31 – 2.10 (m, 1H), 1.52 – 1.40 (m, J = 16.1, 5.7 Hz, 2H), 1.33 (d, J = 2.9 Hz, 
3H), 1.27 (d, J = 2.9 Hz, 3H), 1.25 (s, 9H), 1.21 (s, 9H), 1.16 (s, 9H), 1.09 (s, 9H), 0.94 – 0.72 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 177.87, 177.32, 177.09, 176.78, 140.39, 133.27, 129.32, 128.48, 
106.11, 86.26, 71.56, 71.35, 70.36, 68.55, 67.37, 66.56, 61.58, 59.48, 51.95, 39.00, 38.74, 38.72, 38.69, 
30.04, 29.68, 27.24, 27.14, 27.13, 27.08, 23.60, 21.93. HR-ESI-MS: Calcd for C40H62ClNO11 [M+H]+: 
768.4084, found: 768.4067. 
 
(2R,3R)-2-isopropoxy-3-[(S)-4-fluorophenyl(2,3,4,6-tetra-O-pivaloyl-β-D-galactos
ylamino)methyl]tetrahydro-2H-furan (4fb) 
 
1H NMR (400 MHz, CDCl3) δ 7.22 (dd, J = 8.5, 5.5 Hz, 2H), 6.98 (t, J = 8.6 Hz, 2H), 5.36 (d, J = 2.2 
Hz, 1H), 5.11 (d, J = 4.4 Hz, 1H), 5.08 – 4.97 (m, 2H), 4.17 (dd, J = 11.1, 6.8 Hz, 1H), 4.04 – 3.89 (m, 
3H), 3.85 – 3.67 (m, J = 19.5, 9.2, 5.0 Hz, 4H), 2.30 – 2.11 (m, 1H), 1.50 – 1.35 (m, 2H), 1.33 (d, J = 
6.1 Hz, 3H), 1.27 (d, J = 6.1 Hz, 3H), 1.25 (s, 9H), 1.21 (s, 9H), 1.15 (s, 9H), 1.09 (s, 9H). 13C NMR 
(101 MHz, CDCl3) δ 177.89, 177.33, 177.12, 176.81, 137.54, 137.51, 129.48, 129.40, 115.24, 115.03, 
106.15, 86.24, 71.52, 71.36, 70.36, 68.54, 67.37, 66.58, 61.59, 59.41, 52.06, 39.00, 38.73, 38.69, 30.09, 
27.23, 27.14, 27.12, 27.07, 23.61, 21.94. HR-ESI-MS: Calcd for C40H62FNO11 [M+H]+: 752.4379, 
found: 752.4363. 
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(2R,3R)-2-isopropoxy-3-[(S)-4-bromophenyl(2,3,4,6-tetra-O-pivaloyl-β-D-galacto
sylamino)methyl]tetrahydro-2H-furan (4gb) 
 
1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 8.3 Hz, 2H), 7.15 (d, J = 8.4 Hz, 2H), 5.36 (d, J = 2.1 Hz, 
1H), 5.11 (d, J = 4.4 Hz, 1H), 5.08 – 4.98 (m, 2H), 4.16 (dd, J = 11.1, 6.8 Hz, 1H), 4.03 – 3.89 (m, 3H), 
3.85 – 3.69 (m, 4H), 2.32 – 2.08 (m, 1H), 1.50 – 1.35 (m, 2H), 1.33 (d, J = 6.1 Hz, 3H), 1.27 (d, J = 6.1 
Hz, 3H), 1.25 (s, 9H), 1.21 (s, 9H), 1.16 (s, 9H), 1.09 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 177.88, 
177.34, 177.09, 176.79, 140.91, 131.44, 129.70, 121.37, 106.09, 86.25, 71.56, 71.34, 70.37, 68.55, 
67.36, 66.57, 61.58, 59.53, 51.89, 39.00, 38.74, 38.72, 38.69, 30.04, 29.68, 27.25, 27.14, 27.13, 27.08, 
23.60, 21.93. HR-ESI-MS: Calcd for C40H62BrNO11 [M+H]+: 812.3579, found: 812.3570. 
 
General procedure for the release of the chiral auxiliary 
A solution of compound 4ea (0.15mmol) in dry methanol (1.5 mL) was treated 
with a freshly prepared (0.5 M) solution of sodium methoxide (1 mL), which was 
prepared from sodium and dry methanol. The solution was stirred until the reactant 
was consumed (TLC control). After few drops of water added, the solution was 
neutralized with acetic acid. Then the solution was stirred for another 4 h. The 
solution was extracted with EtOAc, washed with saturated aqueous NaHCO3, dried 
over MgSO4, filtered, and the volatiles were removed under vacuum. The residue was 
purified by column chromatography on silica gel (petroleum ether/ethyl acetate = 1/2, 
with 0.1% Et3N), yielding the corresponding compound 5ea. 
 
(2R,3R)-2-isopropoxy-3-[(S)-4-chlorophenyl(amino)methyl]tetrahydro-2H-pyran 
(5ea) 
 
1H NMR (400 MHz, CDCl3) δ 7.29 (d, J = 8.5 Hz, 2H), 7.23 (d, J = 8.5 Hz, 2H), 4.51 (d, J = 6.1 Hz, 
1H), 4.42 – 4.20 (m, 1H), 4.13 – 3.98 (m, 1H), 3.97 – 3.87 (m, 1H), 3.58 – 3.25 (m, 1H), 1.61 – 1.36 
(m, 4H), 1.25 (dd, J = 18.7, 6.1 Hz, 7H), 1.12 (d, J = 6.1 Hz, 1H), 1.01 – 0.82 (m, 1H) 13C NMR (101 
MHz, CDCl3) δ 142.78, 132.68, 128.82, 128.45, 101.27, 69.33, 63.90, 56.38, 46.77, 24.04, 23.92, 23.71, 
21.67. HR-ESI-MS: Calcd for C15H22ClNO2 [M+H]+: 284.1411, found: 284.1411. 
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